The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Wang, Xin ^a   Mazurkiewicz, Magdalena ^b   Hillert, Ellin Kristina ^b   Olofsson, Maria Hägg ^b   Pierrou, Stefan ^c   Hillertz, Per ^d   Gullbo, Joachim ^e   Selvaraju, Karthik ^a   Paulus, Aneel ^f   Akhtar, Sharoon ^f   Bossler, Felicitas ^g   Khan, Asher Chanan ^f   Linder, Stig ^a,b   D'Arcy, Padraig ^a  

^a LINKÖPING UNIVERSITY   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Life Sciences Consulting AB   (Sweden)

^d Biosynchro in West AB   (Sweden)

^e UPPSALA UNIVERSITY   (Sweden)

^f MAYO CLINIC   (United States)

^g GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZEPINE DERIVATIVE; BENZYLIDENE DERIVATIVE; POLYUBIQUITIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN BINDING; UBIQUITIN THIOLESTERASE; UCHL5 PROTEIN, HUMAN; USP14 PROTEIN, HUMAN; VLX1570;

ANIMAL; ANTAGONISTS AND INHIBITORS; APOPTOSIS; CELL PROLIFERATION; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; DRUG SCREENING; ENZYME STABILITY; FEMALE; HUMAN; METABOLISM; MULTIPLE MYELOMA; PROTEIN DEGRADATION; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZEPINES; BENZYLIDENE COMPOUNDS; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; ENZYME STABILITY; FEMALE; HUMANS; MICE, SCID; MULTIPLE MYELOMA; POLYUBIQUITIN; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEASOME INHIBITORS; PROTEIN BINDING; PROTEOLYSIS; UBIQUITIN THIOLESTERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84974705319     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep26979     Document Type: Article

References (52)

1. Hershko, A. & Ciechanover, A. The ubiquitin system. Ann Rev Biochem 67, 425-479 (1998).
2. Groll, M. et al. Structure of 20S proteasome from yeast at 2.4 A resolution. Nature 386, 463-471 (1997).
3. Goldberg, A. L. Functions of the proteasome: from protein degradation and immune surveillance to cancer therapy. Biochem Soc Trans 35, 12-17 (2007).
4. Groll, M. et al. The catalytic sites of 20S proteasomes and their role in subunit maturation: a mutational and crystallographic study. Proc Natl Acad Sci USA 96, 10976-10983 (1999).
5. Lee, M. J., Lee, B. H., Hanna, J., King, R. W. & Finley, D. Trimming of ubiquitin chains by proteasome-associated deubiquitinating enzymes. Mol Cell Proteomics 10, R110 003871 (2011).
6. D'Arcy, P., Wang, X. & Linder, S. Deubiquitinase inhibition as a cancer therapeutic strategy. Pharmacolgy & Therapeutics 15, 32-54 (2014).
7. Yao, T. & Cohen, R. E. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419, 403-407 (2002).
8. Adams, J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417-421 (2004).
9. Richardson, P. G. et al. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. New Engl J Med 352, 2487-2498 (2005).
10. Varga, C. et al. Novel targeted agents in the treatment of multiple myeloma. Hematol Oncol Clin North Am 28, 903-925 (2014).
11. Chen, S. et al. Genome-wide siRNA screen for modulators of cell death induced by proteasome inhibitor bortezomib. Cancer Res 70, 4318-4326 (2010).
12. D'Arcy, P. et al. Inhibition of proteasome deubiquitinating activity as a new cancer therapy. Nat Med 17, 1636-1640 (2011).
13. Koulich, E., Li, X. & DeMartino, G. N. Relative structural and functional roles of multiple deubiquitylating proteins associated with mammalian 26S proteasome. Mol Biol Cell 19, 1072-1082 (2008).
14. Wang, X. et al. The 19S Deubiquitinase inhibitor b-AP15 is enriched in cells and elicits rapid commitment to cell death. Mol Pharm 85, 932-945 (2014).
15. Coughlin, K. et al. Small-molecule RA-9 inhibits proteasome-associated DUBs and ovarian cancer in vitro and in vivo via exacerbating unfolded protein responses. Clin Cancer Res 20, 3174-3186 (2014).
16. Liu, N. et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget 5, 5453-5471 (2014).
17. Kapuria, V. et al. Deubiquitinase inhibition by small-molecule WP1130 triggers aggresome formation and tumor cell apoptosis. Cancer Res 70, 9265-9276 (2010).
18. Zhou, B. et al. Deubiquitinase inhibition of 19S regulatory particles by 4-arylidene curcumin analog AC17 causes NF-kappaB inhibition and p53 reactivation in human lung cancer cells. Mol Cancer Ther 12, 1381-1392 (2013).
19. Wang, X. et al. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des 86, 1036-1048 (2015).
20. Borodovsky, A. et al. A novel active site-directed probe specific for deubiquitylating enzymes reveals proteasome association of USP14. EMBO J 20, 5187-5196 (2001).
21. Aleo, E., Henderson, C. J., Fontanini, A., Solazzo, B. & Brancolini, C. Identification of new compounds that trigger apoptosomeindependent caspase activation and apoptosis. Cancer Res 66, 9235-9244 (2006).
22. Bazzaro, M. et al. alpha,beta-Unsaturated carbonyl system of chalcone-based derivatives is responsible for broad inhibition of proteasomal activity and preferential killing of human papilloma virus (HPV) positive cervical cancer cells. J Med Chem 54, 449-456 (2011).
23. Martinez Molina, D. et al. Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. Science 341, 84-87 (2013).
24. Chauhan, D., Hideshima, T., Mitsiades, C., Richardson, P. & Anderson, K. C. Proteasome inhibitor therapy in multiple myeloma. Mol Cancer Ther 4, 686-692 (2005).
25. Tian, Z. et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 125, 706-716 (2013).
26. Hamamura, R. S. et al. Induction of heme oxygenase-1 by cobalt protoporphyrin enhances the antitumour effect of bortezomib in adult T-cell leukaemia cells. Br J Cancer 97, 1099-1105 (2007).
27. Brnjic, S. et al. Induction of tumor cell apoptosis by a proteasome deubiquitinase inhibitor is associated with oxidative stress. Antiox Redox Signal 21, 2271-2285 (2014).
28. Koong, A. C., Chauhan, V. & Romero-Ramirez, L. Targeting XBP-1 as a novel anti-cancer strategy. Cancer Biol Ther 5, 756-759 (2006).
29. Anchoori, R. K. et al. A bis-benzylidine piperidone targeting proteasome ubiquitin receptor RPN13/ADRM1 as a therapy for cancer. Cancer Cell 24, 791-805 (2013).
30. Yao, T. et al. Proteasome recruitment and activation of the Uch37 deubiquitinating enzyme by Adrm1. Nature Cell Biol 8, 994-1002 (2006).
31. Wang, X. et al. Mass spectrometric characterization of the affinity-purified human 26S proteasome complex. Biochemistry 46, 3553-3565 (2007).
32. Galluzzi, L. & Kroemer, G. Necroptosis: a specialized pathway of programmed necrosis. Cell 135, 1161-1163 (2008).
33. Mines, M. A., Goodwin, J. S., Limbird, L. E., Cui, F. F. & Fan, G. H. Deubiquitination of CXCR4 by USP14 is critical for both CXCL12-induced CXCR4 degradation and chemotaxis but not ERK ativation. J Biol Chem 284, 5742-5752 (2009).
34. Wang, Y. et al. Ubiquitin-specific protease 14 (USP14) regulates cellular proliferation and apoptosis in epithelial ovarian cancer. Med Oncol 32, 379 (2015).
35. Huang, G., Li, L. & Zhou, W. USP14 activation promotes tumor progression in hepatocellular carcinoma. Oncol Rep 34, 2917-2924 (2015).
36. Tian, Z. et al. A novel small molecule inhibitor of deubiquitylating enzyme USP14 and UCHL5 induces apoptosis in multiple myeloma and overcomes bortezomib resistance. Blood 123, 706-716 (2014).
37. Richardson, P. G., Mitsiades, C., Hideshima, T. & Anderson, K. C. Proteasome inhibition in the treatment of cancer. Cell Cycle 4, 290-296 (2005).
38. Obeng, E. A. et al. Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells. Blood 107, 4907-4916 (2006).
39. Lee, B. H. et al. Enhancement of proteasome activity by a small-molecule inhibitor of USP14. Nature 467, 179-184 (2010).
40. Homma, T. et al. Ubiquitin-specific protease 14 modulates degradation of cellular prion protein. Sci Reports 5, 11028 (2015).
41. Wilson, S. M. et al. Synaptic defects in ataxia mice result from a mutation in Usp14, encoding a ubiquitin-specific protease. Nat Genet 32, 420-425 (2002).
42. Vaden, J. H. et al. Ubiquitin-specific protease 14 regulates c-Jun N-terminal kinase signaling at the neuromuscular junction. Mol Neurodegener 10, 3 (2015).
43. Mullally, J. E. & Fitzpatrick, F. A. Pharmacophore model for novel inhibitors of ubiquitin isopeptidases that induce p53-independent cell death. Mol Pharm 62, 351-358 (2002).
44. Ritorto, M. S. et al. Screening of DUB activity and specificity by MALDI-TOF mass spectrometry. Nat Comms 5, 4763 (2014).
45. Witz, G. Biological interactions of alpha,beta-unsaturated aldehydes. Free Rad Biology Med 7, 333-349 (1989).
46. Ploemen, J. H., Van Schanke, A., Van Ommen, B. & Van Bladeren, P. J. Reversible conjugation of ethacrynic acid with glutathione and human glutathione S-transferase P1-1. Cancer Res 54, 915-919 (1994).
47. Husnjak, K. et al. Proteasome subunit Rpn13 is a novel ubiquitin receptor. Nature 453, 481-488 (2008).
48. Jafari, R. et al. The cellular thermal shift assay for evaluating drug target interactions in cells. Nat Protoc 9, 2100-2122 (2014).
49. Friedrich, J. et al. A reliable tool to determine cell viability in complex 3-d culture: the acid phosphatase assay. J Biomol Screen 12, 925-937 (2007).
50. Steinbrunn, T., Chatterjee, M., Bargou, R. C. & Stuhmer, T. Efficient transient transfection of human multiple myeloma cells by electroporation-an appraisal. PloS one 9, e97443 (2014).
51. Biven, K. et al. A novel assay for discovery and characterization of pro-apoptotic drugs and for monitoring apoptosis in patient sera. Apoptosis 8, 263-268 (2003).
52. Niewerth, D. et al. Molecular basis of resistance to proteasome inhibitors in hematological malignancies. Drug Res Updates 18, 18-35 (2015).